Don Rule

Don Rule

Don founded Translational Software® to accelerate the use of molecular diagnostics. Prior to this he had a 14 year career at Microsoft, holding a variety of roles in providing Internet access to MSN, pioneering Virtual Private Networking products, and integrating Instant Messaging with Voice Over IP networks. Don founded the BioIT Alliance from within Microsoft to accelerate collaboration in translational research.

Read recent posts by this author below »

PGx Testing: Why Success Requires More Than Just Launching a Program

Pharmacogenomic (PGx) testing allows healthcare providers to make more informed, evidence-based decisions for their patients. To take advantage of this new clinical tool, we’ve recently seen several large

Recent Developments in Pharmacogenomics

For more than a decade, a robust body of evidence has progressively unveiled drug-genome interactions with important implications for health. Yet doctors and many health-care systems have been slow to implement

What You Need To Know About These 3 Newly Approved Drug-Genome Interactions

In 2018, 59 new medications earned FDA approval. Multigene pharmacogenomics (PGx) panels can safely prescribe three of these new drugs to prevent unnecessary toxicities and drug-genome interactions. A decade ago,

Exploring the Knowledge and Perspectives of US Payers on Preemptive Pharmacogenetic Testing

When it comes to wide-scale adoption of pharmacogenomics (PGx) testing, reimbursement has been one of the industry’s biggest roadblocks. This is especially true when it comes to the preemptive testing model. While

A Global Perspective on Consumer and Healthcare Genomics

I was honored to be invited by Illumina to speak at their Consumer and Healthcare Genomics Summit in Bangkok on May 8. Illumina had assembled an eclectic group of their experienced customers as well as vendors that